

Updates and Evolving Care Considerations in the Mitigation of Hyperkalemia in Patients with End-Stage Renal Disease on Dialysis – Twitter Chat #2

References

Topic 1

Fishbane S, Ford M, Fukagawa M, et al. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. *J Am Soc Nephrol*. 2019;30(9):1723-1733. doi:10.1681/ASN.2019050450

Montford JR, Linas S. How dangerous is hyperkalemia? *J Am Soc Nephrol*. 2017;28:3155-3165.

National Kidney Foundation. *Best Practices in Managing Hyperkalemia in Chronic Kidney Disease.*; 2016. https://www.kidney.org/sites/default/files/02-10-7259_DBH_Best-Practices-in-Managing-Hyperkalemia-in-CKD.pdf.

Palmer BF, Clegg DJ. Hyperkalemia across the Continuum of Kidney Function. *Clin J Am Soc Nephrol*. 2018;13(1):155-157. doi:10.2215/CJN.09340817

Topic 2

AstraZeneca. [sodium zirconium cyclosilicate (SZC)] demonstrated efficacy in treating hyperkalemia in patients with end-stage renal disease on haemodialysis. Press Release. <https://www.astrazeneca.com/media-centre/press-releases/2019/lokelma-demonstrated-efficacy-in-treating-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis14062019.html>. Published 2019.

AstraZeneca. [sodium zirconium cyclosilicate (SZC)] US label updated to include dosing guidance for the treatment of hyperkalaemia in patients with end-stage renal disease on haemodialysis. Press Release. <https://www.astrazeneca.com/media-centre/medical-releases/lokelma-us-label-updated-to-include-dosing-guidance-for-the-treatment-of-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis.html>. Published 2020.

Bavry A, Bhatt DL. Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease - AMBER. *Am Coll Cardiol*. 2019. <https://www.acc.org/latest-in-cardiology/clinical-trials/2019/10/08/14/26/amber>.

Bianchi S, Regolisti G. Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc*. 2019;34(Suppl 3):iii51-iii61. doi:10.1093/ndt/gfz213

Leon SJ, Harasemiw O, Tangri N. New therapies for hyperkalemia. *Curr Opin Nephrol Hypertens*. 2019;28(3):238-244. doi:10.1097/MNH.0000000000000500

Pani A, Floris M, Rosner MH, Ronco C. Hyperkalemia in hemodialysis patients. *Semin Dial*. 2014;27(6):571-576. doi:10.1111/sdi.12272

Seliger SL. Hyperkalemia in patients with chronic renal failure. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc*. 2019;34(Suppl 3):iii12-iii18. doi:10.1093/ndt/gfz231

Topic 3

AstraZeneca. [sodium zirconium cyclosilicate (SZC)] demonstrated efficacy in treating hyperkalaemia in patients

with end-stage renal disease on haemodialysis. Press Release. <https://www.astrazeneca.com/media-centre/press-releases/2019/lokema-demonstrated-efficacy-in-treating-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis14062019.html>. Published 2019.

AstraZeneca. [sodium zirconium cyclosilicate (SZC)] US label updated to include dosing guidance for the treatment of hyperkalaemia in patients with end-stage renal disease on haemodialysis. Press Release. <https://www.astrazeneca.com/media-centre/medical-releases/lokema-us-label-updated-to-include-dosing-guidance-for-the-treatment-of-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis.html>. Published 2020.

Bianchi S, Regolisti G. Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc*. 2019;34(Suppl 3):iii51-iii61. doi:10.1093/ndt/gfz213

Leon SJ, Harasemiw O, Tangri N. New therapies for hyperkalemia. *Curr Opin Nephrol Hypertens*. 2019;28(3):238-244. doi:10.1097/MNH.0000000000000500

Pitt B, Bakris GL. New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. *Hypertension*. 2015;66:731-738.

US FDA. *Patiromer Prescribing Information*.; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205739s016lbl.pdf.

US FDA. *Sodium Zirconium Cyclosilicate Prescribing Information*.; 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207078s003lbl.pdf.

Topic 4

AstraZeneca. [sodium zirconium cyclosilicate (SZC)] US label updated to include dosing guidance for the treatment of hyperkalaemia in patients with end-stage renal disease on haemodialysis. Press Release. <https://www.astrazeneca.com/media-centre/medical-releases/lokema-us-label-updated-to-include-dosing-guidance-for-the-treatment-of-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis.html>. Published 2020.

Bianchi S, Regolisti G. Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc*. 2019;34(Suppl 3):iii51-iii61. doi:10.1093/ndt/gfz213

De Nicola L, Lullo LD, Paoletti E, Cupisti A, Bianchi S. Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice. *J Nephrol*. 2018;31:653-664. doi:10.1007/s40620-018-0502-6

Leon SJ, Harasemiw O, Tangri N. New therapies for hyperkalemia. *Curr Opin Nephrol Hypertens*. 2019;28(3):238-244. doi:10.1097/MNH.0000000000000500

Pitt B, Bakris GL. New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. *Hypertension*. 2015;66:731-738.

Sodium Polystyrene Sulfonate package insert. July 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/011287s026lbl.pdf

US FDA. *Patiromer Prescribing Information*.; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205739s016lbl.pdf.

US FDA. *Sodium Zirconium Cyclosilicate Prescribing Information.*; 2020.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207078s003lbl.pdf.

Topic 5

Bakris GL, Pitt B, Weir MR *et al.* Effect of patiomer on serum potassium level in patients with hyperkalemia and diabetic kidney disease the AMETHYST-DN randomized clinical trial. *JAMA* 2015;**314**:151–161. <https://doi.org/10.1001/jama.2015.7446>

Fishbane S, Ford M, Fukagawa M, et al. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. *J Am Soc Nephrol*. 2019;**30**(9):1723-1733. doi:10.1681/ASN.2019050450

Hon-Ting Wai, Nirmol Meah, Ravish Katira. Novel potassium binders: a clinical update. *Brit Jour of Card*. 2021; doi:10.5837/bjc.2021.014

Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. *JAMA*. 2014;**312**(21):2223-2233. doi:10.1001/jama.2014.15688

Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. *N Engl J Med*. 2015;**372**(3):222-231. doi:10.1056/NEJMoa1411487

Pitt B, Anker SD, Bushinsky DA *et al.* Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. *Eur Heart J*. 2011;**32**:820–828. <https://doi.org/10.1093/eurheartj/ehq502>

Roger SD, Spinowitz BS, Lerma EV, et al. Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE. *Am J Nephrol*. 2019;**50**(6):473-480. doi:10.1159/000504078

Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. *Clin J Am Soc Nephrol*. 2019;**14**(6):798-809. doi:10.2215/CJN.12651018

Weir MR, Bakris GL, Bushinsky DA *et al.* Patiomer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. *N Engl J Med* 2015;**372**:211–221. <https://doi.org/10.1056/NEJMoa1410853>

Topic 6

Kristensen SL, Docherty KF, Jhund PS, et al. Dapagliflozin reduces the risk of hyperkalemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF. Presented at ESC Virtual Congress 2020, August 29, 2020.

McMurray JJV, DeMets DL, Inzucchi SE, et al. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. *Eur J Heart Fail*. 2019;**21**(11):1402- 1411. <https://doi.org/10.1002/ejhf.1548>

Topic 7

AstraZeneca. [sodium zirconium cyclosilicate (SZC)] US label updated to include dosing guidance for the treatment of hyperkalaemia in patients with end-stage renal disease on haemodialysis. Press Release.

<https://www.astrazeneca.com/media-centre/medical-releases/lokema-us-label-updated-to-include-dosing-guidance-for-the-treatment-of-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis.html>. Published 2020.

Fishbane S, Ford M, Fukagawa M, et al. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. *J Am Soc Nephrol*. 2019;30(9):1723-1733. doi:10.1681/ASN.2019050450

Topic 8

Betts KA, Woolley JM, Mu F, et al. Postdischarge health care costs and readmission in patients with hyperkalemia-related hospitalizations. *Kidney Int Rep*. 2020;5(8):1280-1290. doi:10.1016/j.ekir.2020.06.004

Topic 9

Núñez J, Bayés-Genís A, Zannad F, et al. Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. *Circulation*. 2018;137(13):1320-1330. doi:10.1161/CIRCULATIONAHA.117.030576

Rosano GMC, Tamargo J, Kjeldsen KP, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. *Eur Heart J Cardiovasc Pharmacother*. 2018;4(3):180-188. doi:10.1093/ehjcvp/pvy015

Saito Y, Yamamoto H, Nakajima H, Takahashi O, Komatsu Y. Incidence of and risk factors for newly diagnosed hyperkalemia after hospital discharge in non-dialysis-dependent CKD patients treated with RAS inhibitors. *PLoS One*. 2017;12(9):e0184402. doi:10.1371/journal.pone.0184402

Glossary

ACE, Angiotensin-converting enzyme
Adv, advanced
AEs, adverse effects
ARB, angiotensin-receptor blockers
 Ca^{2+} , calcium ion
CV, cardiovascular
CVD, cardiovascular disease
D, day
DM, Diabetes mellitus
Ed, emergency department
Ef, ejection fraction
ESRD, end-stage renal disease
Est, establish
FDA, Food and Drug Administration
FX, function
G, gram
GI, gastrointestinal
 H^+ , hydrogen
 H_2O , water
HD, hemodialysis
HF, heart failure
HK, hyperkalemia
Hr, hour
HyperK, hyperkalemia
 K^+ , potassium
Mg/dl, milligrams per deciliter
Mgmt., management
Mo, months
MOA, mechanism of action
MRA, Mineralocorticoid receptor antagonists
 Na^+ , sodium
Nnt, number-needed-to-treat
NSAID, Non-steroidal anti-inflammatory drugs
Op, outpatient department
PBO, placebo
pop, population
Prev, previously
Pts, patients
Qd, once daily
RAASi, Renin-angiotensin-aldosterone system inhibitors
SAE, serious adverse event
SPS, sodium polystyrene sulfonate
SZC, Sodium zirconium cyclosilicate
Tx, treatment
Vs, versus
w/, with
Wk, week
X, times
~, about

